Celldex Therapeutics CLDX Business Segments — Supplies Expense

Similar metrics at other companies

ARD

ARDTReportable Segment — Supplies

$268.55M+3.7%

LQD

LQDASingle Reportable — Program Expenses

$21.66M+64.4%

RXRXReportable Segment — Consumables

$7.15M-86.9%

ROLReportable Segment — Materials and supplies

$53.22M+9.7%

QURESingle Reportable — Facility Expenses

$1.55M-7.2%

IOVASingle Reportable — Operating Expenses

$107.98M-12.1%

Questions, answered.

What is Celldex Therapeutics's business segments — supplies expense?

Celldex Therapeutics (CLDX) reported business segments — supplies expense of $1.46M in Q1 2026.

How has Celldex Therapeutics's business segments — supplies expense changed year-over-year?

Celldex Therapeutics's business segments — supplies expense decreased by 32.7% year-over-year, from $2.17M to $1.46M.

What is the long-term trend for Celldex Therapeutics's business segments — supplies expense?

Over 3 years (2022 to 2025), Celldex Therapeutics's business segments — supplies expense has grown at a -1.7% compound annual growth rate (CAGR), from $6.31M to $6M.

What does business segments — supplies expense mean?

This metric tracks the costs of materials, laboratory consumables, and other physical supplies consumed during the research and development process within the primary business segment. It serves as a measure of the operational intensity of the company's clinical and laboratory activities. Fluctuations in this metric can indicate changes in the volume or complexity of ongoing experimental programs.